NASDAQ, APCVZ - Fresenius Kabi Pharmaceuticals Holding Inc.
Unless the context otherwise requires, references in this report to ?Fresenius
Kabi Pharmaceuticals,? ?FKP Holdings, Inc.,? ?FKP Holdings,? ?the Company,?
?we,? ?us? and ?our? refer to ?Fresenius Kabi Pharmaceuticals Holding, Inc. and
its subsidiaries, including our operating subsidiary APP Pharmaceuticals, Inc,
or ?APP? (and its subsidiaries APP Pharmaceuticals, LLC, APP Pharmaceuticals
Manufacturing, LLC, and Pharmaceutical Partners of Canada, Inc.). References to
?the Merger? refer to the Merger between a subsidiary of FKP Holdings, an
indirect wholly owned subsidiary of Fresenius SE (?Fresenius?), a societas
europaea organized under the laws of the European Union and Germany, and APP.
References to ?New APP,? and ?APP Pharmaceuticals,? refer to the company prior
to the merger with FKP Holdings and after the separation from Abraxis
BioScience, Inc. in 2007. References to ?Old Abraxis? refer to Abraxis
BioScience, Inc. ...
Read SEC Filing on NASDAQ.com »